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Abstract
Chronic obstructive pulmonary disease (COPD) is a global health problem. As understanding of
pathology of COPD has increased it has been established that COPD is associated with the
progressive pulmonary inflammation and destruction of lung parenchyma (emphysema) that relate
to disease severity. Therefore, it is anticipated that drugs that reduce pulmonary inflammation will
provide effective, disease modifying therapy for COPD. Several specific therapies are directed
against the influx of inflammatory cells into the airways and lung parenchyma that occurs in COPD;
these include agents directed against cytokines and chemokines. Broad-range anti-inflammatory
drugs are now in phase III development for COPD; they include inhibitors of phosphodiesterase 4
(PDE4). Other drugs that inhibit cell signaling include inhibitors of p38 mitogen-activated protein
kinase (MAPK), nuclear factor-κB (NF-κB), and phosphoinositide-3-kinase (PI3K). There is also a
search for inhibitors of proteinases and matrix metalloproteinases (MMPs) to prevent lung
destruction and the development of emphysema. This review highlights studies on novel or potential
anti-inflammatory agents that might be considered in the development of new future therapies for
COPD.
Keywords
NF-κB; MAP kinase; MMPs; cigarette smoke; cytokines; antagonists
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality
worldwide with an overall prevalence in adults over 40 years currently estimated at between
9 and 10% [1]. The World Health Organization predicts that by 2020 COPD will be the 5th
most prevalent disease worldwide (presently the 12th) and the 3rd most common cause of death
(presently the 6th). The prevalence is estimated to be about 1% worldwide, but is about 2 times
higher in Western societies, and often underestimated due to un- or misdiagnosis [2–4]. The
burden of COPD for the patient is high as patients experience a poorer quality of life, suffer
from comorbidites (3.7 comorbidities per patient), and direct healthcare costs 20.9 billion dollar
in the USA in 2004 [5–8]. In Western countries the major cause is tobacco smoking, whereas
in developing countries also indoor pollution e.g. from cooking is a cause. Other risk factors
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for COPD include genetic predisposition, occupational and environmental exposure, and
asthma. More than 90% of patients with COPD are smokers [9], but 30%–40% of the smokers
estimated to develop COPD [10] pointing at an additional risk factor for, e.g. genetic variability
contributes to smoke susceptibility [11].
COPD is a chronic lung inflammatory disease with a systemic component characterized by
chronic obstruction of lung airflow that progressively deteriorates over time and relatively
insensitive to treatment with bronchodilators which provide mainly symptomatic relief by
reducing hyperinflation. Classically COPD involves two major spectra of clinical or
pathological presentations, chronic bronchitis and emphysema. Inflammation in COPD lungs
is present in both small and large airway, alveoli and vasculature and is thought to be critical
in the development of the pathology of the disease [12,13]. Indeed the severity of inflammation
is associated with disease severity as measured by spirometry [14]. In small airway
inflammation, fibrosis, smooth muscle hypertrophy, globlet cell hyperplasia are present and
these features increase in intensity as the disease progresses. Inflammatory cell involved in the
small airways consists of CD4 and CD8+ T lymphocyte, B cell follicles, macrophages and in
more severe disease neutrophils [15]. Inflammation is also present in large airways and consists
of macrophages, CD8+ lymphocytes, neutrophils and plasma cells [16]. Pro-inflammatory
mediators, including cytokines and chemokines are released by both structural and
inflammatory cells, attracting more inflammatory cells and creating a positive inflammatory
loop that enhances and maintains the inflammatory response. In addition, there is accumulation
of neutrophils to the airways of smokers without any significant COPD, emphasizing the pro-
inflammatory effects of cigarette smoke which is one of the risk factors for COPD.
Inflammation in COPD and emerging anti-inflammatory therapy is shown in Figure 1.
Interestingly, the pattern of inflammation of COPD is similar no matter what region of the lung
is sampled histopathologically, albeit the marked neutrophilia seen in induced sputum is not
seen in bronchial biopsies in stable disease and is distinct to that seen in bronchoalveolar lavage
fluid [17]. Thus, COPD develops as a result of the participation of a variety of inflammatory
cells and mediators contributed by cells and mediators that originate from both innate and
adaptive immune responses.
2. Aim of therapy
The aim of therapy for COPD is not only to treat symptoms and complications as early as
possible and to improve exercise tolerance, but also to reduce the number and severity of
exacerbations in order to prevent progressive deterioration of health status and lung function.
Smoking cessation is still the only significant way to slow the progression of COPD even
though all kinds of therapies developed. Current therapy focused mainly on reduction of
symptoms using short and long acting bronchodilators either as mono-therapies or combination
of long acting β2 agonist bronchodilators with inhaled corticosteroids [18,19]. Recent TORCH
studies showed that a combination of long-acting beta-agonists (salmeterol) with inhaled
corticosteroids (fluticasone propionate) offers statistically significant advantages for reducing
the frequency of exacerbations, and- probably most important clinically-protection against a
decline in lung function [20,21]. In addition, combined salmeterol/fluticasone propionate
improves the inflammation in the airways of patients with COPD. This finding confirms the
prospect of this combination therapy in current guidelines for the treatment of patients with
COPD that recommend its use for those with severe COPD with frequent exacerbations but
not for patients with milder disease or without frequent exacerbations. However, a caution in
the use of combination therapy is urged because of the finding in the TORCH trial of an
increased rate of pneumonia among all patients receiving treatment containing inhaled
corticosteroids [20]. Though some recent studies using higher doses or longer duration of
treatment showed reduced airway inflammation and improved quality of life, steroid treatment
of patients with COPD is rather ineffective in improving the decline in lung function [22–
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24]. In addition, adverse effects of steroids including increased risk of hip fractures and
osteoporosis, skin bruising, glaucoma, and cataract is main hurdle for its development for
COPD [25]. Although emphysema may be another factor that is why the results with current
anti-inflammatory therapies have been disappointing, inflammatory cells do actively
participate in the pathogenesis of alveolar destruction. Therefore, the search for effective anti-
inflammatory agents for COPD is emergent and this goal remains a key objective for the
pharmaceutical industry.
3. Development of new anti-inflammatory agents
COPD is a chronic inflammatory disorder, thus a key question is whether novel anti-
inflammatory agents can prevent or slow lung function decline characteristic of COPD that
appears to be insensitive to current therapy. In addition, the relationship between inflammatory
biomarker measured in sputum, bronchoalveolar lavage fluid (BALF), bronchial biopsies or
blood and clinical outcomes including disease progression, disease severity, or response to
therapy is limited and more work is required to understand these key relationships. Trials
examining the predictive value of inflammatory biomarkers are underway but so far the only
markers that show a trend towards differentiation between the different GOLD stages of disease
severity are arterial oxygen tension, sputum neutrophils and IL-8, and serum TNF-α and C-
reactive protein [26,27]. The spirometric GOLD classification of severity of COPD now only
includes four stages- Stage I: Mild; Stage II: Moderate; Stage III: Severe; Stage IV: Very Severe
[28]. Stage 0: At Risk,”-that appeared in the 2001 report is no longer included as a stage of
COPD, as there is incomplete evidence that the individuals who meet the definition of “At
Risk” (chronic cough and sputum production, normal spirometry) necessarily progress on to
Stage I [28]. The final part of this review focuses on the recent developments and advances in
potential anti-inflammatory agents for treatment of COPD.
3.1. Inhibitors of cell signaling pathway
3.1.1. Phosphodiesterase 4 (PDE4) inhibitors—PDE4 is the predominant PDE
isoenzyme in most inflammatory cells though to have a role in COPD pathogenesis and its
activity is elevated in lung macrophages from COPD patients [29]. In contrast to the studies
that steroids have limited anti-inflammatory efficacy in cigarette smoke models both in the
mouse and guinea pig, there are increasing numbers of references documenting the in vivo
efficacy of PDE4 inhibitor in animal models of COPD. There are currently five oral PDE4
inhibitors (roflumilast, Phase III from Altana; cilomilast, Phase III from GSK; GRC3886,
Phase II from Glenmark; tetomilast, Phase II from Otsuka; C1393, Phase II but suspended from
Merck) in clinical development for COPD.
In 24 weeks Phase multi-center III trails in COPD patients (RECORD trial), oral administration
of roflumilast or cilomilast improved pre- and post-bronchodilator FEV1 [30,31]. The health-
related quality of life (SGRQ) was also improved when compared to the placebo control. In
addition, exacerbation frequency was lower in drugs group than in the placebo group.
The relationship between these improvements in clinical outcome and potential anti-
inflammatory activity has been investigated in a single study [32,33]. After a 4 week treatment
with roflumilast post-bronchodilator FEV1 improved by 68.7 ml compared with placebo.
Treatment with roflumilast significantly reduced the absolute numbers of neutrophils and
eosinophils of sputum. These were paralleled with by a reduction in IL-8 and neutrophil
elastase. Although 12 weeks treatment with cilomilast had no effect on sputum neutrophils,
macrophages, elastase, IL-8 or lung function; bronchial biopsies demonstrated that cilomilast
treatment was associated with significant reductions in CD8+ T lymphocyte and CD68+ cells.
The results showed that related outcomes observed in longer term trials could be due, at least
in part, to anti-inflammatory activity of drugs.
Yao et al. Page 3
Curr Respir Med Rev. Author manuscript; available in PMC 2009 August 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
In an attempt to reduce the potential for systemic side effects and to administer relatively higher
doses to the lung, inhaled PDE4 inhibitors are being developed. GSK842470 (AWD-12-281)
was licensed from Elbion and reached Phase II for asthma and COPD but there have been
unconfirmed reports that it had no advantage over oral PDE4 inhibitors. This compound no
longer appears on GSK’s pipeline but remains in development for rhinitis by Elbion. Currently,
GSK (Phase I) and Pfizer (Phase II) are reported to have inhaled PDE4 inhibitors in clinical
development for COPD. In addition, other step might overcome the limitation of side effects.
Vomiting seems likely to be due to inhibition of a particular subtype of PDE4. At least four
human PDE4 genes have been identified, and each has several splice variants [34]. Thus,
subtype-selective inhibitors could be developed that preserve the anti-inflammatory effect,
while having less propensity to cause side-effects. PDE4D seems to be particularly important
in nausea and vomiting and is expressed in the chemosensitive trigger zone in the brainstem
[35]. In mice, deletion of the gene for PDE4D prevents a behavioral equivalent of emesis
[36]. This isoenzyme seems to be less important in anti-inflammatory effects, and targeted
gene-disruption studies in mice have shown that PDE4B is more important than PDE4D in
inflammatory cells [37]. PDE4B selective inhibitors might therefore have a greater therapeutic
ratio and be effective anti-inflammatory drugs.
3.1.2. p38 mitogen-activated protein kinase (MAPK) inhibitors—MAPK play a key
role in chronic inflammation and several complex enzyme cascades have now been defined
[38]. One of these, the p38 MAPK pathway, is activated by cellular stress and regulates the
expression of wide variety of inflammatory cytokines that include IL-8, TNF-α and MMPs
[39] (Figure 2). Small molecule inhibitors of p38 MAPK, such as SB 203580, SB 239063 and
RWJ 67657 having broad range of anti-inflammatory effects have been developed [40].
Administration of SB203580 has beneficial effects in animal disease models such as collagen-
induced arthritis and endotoxin-induced septic shock [41]. SB203580 also inhibits cytokine
production and proliferation that has been induced by mitogen stimulation or T-cell receptor
ligation, with or without CD28-mediated co-stimulation [42–44]. p38 MAPK has also been
shown to upregulate cytokine production by several independent mechanisms, including direct
phosphorylation of transcription factors, and direct or indirect stabilization and increased
translation of mRNAs containing 3% untranslated region adenylate/uridylate-rich elements
(AREs) by phosphorylation of ARE-binding proteins [45–47]. These observations have
attracted interest in p38 MAPK as a molecular target in the treatment of inflammatory human
diseases. Studies in healthy volunteers given p38α/p38β inhibitors found reductions in pro-
inflammatory cytokine secretion from ex-vivo LPS-stimulated peripheral-blood mononuclear
cells [48], and decreased LPS-induced pro-inflammatory cytokine production, neutrophil and
endothelial-cell activation in vivo. SB239063 on the other hand reduces neutrophil infiltration
and the concentrations of IL-6 and MMP-9 in BALF of rats after endotoxin inhalation,
suggesting its potential as an anti-inflammatory agent in COPD [49].
The potential therapeutic utility of p38 MAPK inhibition in respiratory disease has been
supported by data generated in a range of pulmonary inflammatory models in vivo including
LPS induced pulmonary neutrophilia [50], bleomycin induced fibrosis [51], and antigen
induced eosinophilia [52]. A recent study demonstrated the efficacy of p38α MAPK inhibitor,
SD282, in a mouse model of cigarette smoke-induced inflammation. In this model, SD-282
inhibited cigarette smoke induced pulmonary neutrophilia and macrophage recruitment.
Although a number of oral p38 MAPK inhibitors are in clinical development for arthritis and
cancer only two compounds are currently in development for COPD. GSK-681323 is currently
in a 4 week Phase II trial where the efficacy outcome measures include lung function, sputum
and serum biomarkers, including C-reactive protein. GSK-85633 is in Phase I. Although it is
likely that such a broad spectrum anti-inflammatory drug might ensue some toxicity or impair
natural immune responses, but inhalation route might be a feasible therapeutic approach.
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3.1.3. Nuclear factor-κB (NF-κB) inhibitors—Studies with inhibitor of κB (IκB)α
mutants [53,54] gave the first evidence that NF-κB pathway could be specifically inhibited.
Signal-induced phosphorylation and degradation of cytoplasmic IκBα is required for NF-κB
pathway activation. However, an IκBα protein with mutations at serine-32 and 36 is not
phosphorylated by IKK (IκBα kinase) and therefore not degraded by the proteasome. This
IκBα mutant or super-repressor exerts its negative effect by sequestering NF-κB in the
cytoplasm and thus prevents the induction of specific NF-κB target genes.
There are several possible approaches to inhibition of NF-kB, including gene transfer of IκB,
inhibitors of IκB kinases (IKK), NF-κB-inducing kinase and IκB ubiquitin ligase, which
regulate the activity of NF-κB, and inhibit the degradation of IκB [55] (Figure 2). The most
promising approach may be the inhibition of IKK-2 by small molecule inhibitors [56], which
suppress the release of inflammatory cytokines and chemokines from alveolar macrophages
[57] whereas alveolar macrophages are resistant to the anti-inflammatory actions of
corticosteroids. However, it is of concern that long-term inhibition of IKK-2 may result in
immunosuppressive side effect while IKK-1 inhibitor may be another approach to inhibit the
inflammation response in animal models (authors’ unpublished observation). In addition,
alternative modulation of pathways of NF-κB activation via kinases other than IKK might be
a more safer approach in inflammatory disease and would have less potential effect on innate
and adaptive immune responses [58].
Glucocorticoids, such as dexamethasone and prednisone, are widely used for their anti-
inflammatory and immunosuppressive properties. Dexamethasone induces the synthesis of
IκBα mRNA in glucocorticoid receptor-expressing Jurkat cells [59] and in monocytic cells
[60], therefore resulting in the cytoplasmic retention of p65 due to binding of IκBα to the pre-
existing NF-κB complexes [60]. Retention of NF-κB in an inactive cytoplasmic complex thus
down regulates expression of pro-inflammatory genes.
Another novel way whereby NF-κB activity may be regulated is by the use of inhibitors of
proteasome function, which can reduce the degradation of IκB and thus prevent NF-κB
activation [53,54]. A series of peptide aldehydes such as MG101, MG132, and MG115, make
up a family of agents that inhibit the protease activity of the proteasome. Lactacystin, another
class of proteasome inhibitor, blocks proteolytic activity by acylating a threonine residue in
one of the key proteasome subunits. Furthermore, a group of boronic acid peptides, including
PS-341, are extremely potent inhibitors of proteasome function [61], thus inhibiting activation
of the NF-κB pathway. It is also possible that inhibitors of the ubiquitin ligase that mediates
IκB ubiquitination may be a useful target in preventing proteasome degradation of IκB. Thus,
a wide variety of potential inhibitors of proteasome function may have a therapeutic role in
anti- NF-κB pathway dependent strategies.
Certain natural polyphenolic antioxidants/products such as flavonoids quercetin, resveratrol,
and myricetin are also known to mediate their anti-inflammatory properties through down
regulation of the NF-κB pathway [62,63]. For example, resveratrol, which is found in red wine,
can inhibit NF-κB activity and induce apoptosis in transformed cells, which may reduce
mortality from coronary heart diseases, certain cancers and inflammatory diseases [62].
Resveratrol has strong inhibitory effects on iNOS expression and NO generation in activated
macrophages [63]. Since treatment of macrophages with resveratrol blocks LPS-induced
phosphorylation and degradation of IκBα to decrease NF-κB DNA binding activity, is
suggestive of the fact that its anti-inflammatory effects may be due at least in part to the
inhibition of NF-κB-dependent NO synthesis [63]. Thus several of the biological activities of
flavonoids may be mediated by their inhibition of the NF-κB pathway. Indeed, flavanoid
resveratrol inhibits inflammatory cytokine release from macrophages isolated from COPD
patients [57] However, the clinical utility of resveratrol in patients with COPD is not known.
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3.1.4. Phosphoinositide 3-kinases (PI3K) inhibitor—The PI3K are a family of proteins
that catalyze the phosphorylation of the 3-OH position of phosphoinositides and generate lipids
that control a wide variety of intracellular signaling pathways. Recent studies suggested that
numerous components of the PI3K pathway play a crucial role in the expression and activation
of inflammatory mediators, inflammatory cell recruitment, immune cell function and airway
remodeling as well as corticosteroid insensitivity in chronic inflammatory respiratory disease
such as asthma [64–67] (Figure 2).
Although no reports on the effect of PI3K inhibitors on experimental models of COPD have
been published, the data suggesting a potential role of PI3K in the pathogenesis of COPD is
now accumulating. PI3K is important in the activation of macrophage and neutrophils, which
are key players in COPD inflammation [68]. Moreover, MMP-9 degrades extracellular matrix
components (particularly elastin) and is related to the pathogenesis of pulmonary emphysema.
MMP-9 is present in low quantities in the healthy adult lung but much more abundant in COPD
and the inappropriate expression of MMP-9 is thought to contribute to the pathogenesis of
COPD [69]. MMP-9 expression whether stimulated by platelet activating factor or fibronectin,
probably through an action on NF-κB, is also regulated by PI3K signaling pathways [70].
Patients with COPD and severe asthma do not respond well to corticosteroids though
corticosteroids are very effective in controlling mild to moderate asthma. Ito and coworkers
[71] reported a reduction in corepressor, histone deacetylases 2 (HDAC2) expression and total
HDAC activity in COPD patients. By overexpression and knockdown of HDAC2 demonstrated
that HDAC2 is a prerequisite molecule for corticosteroid action in airway macrophages and
reduction of HDAC2 is one of the causes of corticosteroid insensitivity in COPD [72]. In
vitro experiments have also shown that oxidative stress raised by hydrogen peroxide reduced
HDAC2 expression and in preliminary experiments LY294002 (a reversible PI3K inhibitor)
restored defective HDAC2 expression and activity in these cells. Therefore, PI3K inhibitors
will be more efficacious in more severe steroid-insensitive asthma and in COPD where
corticosteroids are of limited effectiveness and no alternative therapy is available.
In addition, non-specific PI3K inhibitors exhibit some compound specific toxicity and possess
off-target effects [wortmannin (an irreversible inhibitor): myosin light chain kinase inhibition,
LY294002: casein kinase-2 inhibition]. As reviewed by Ito and colleague [73], most
inflammatory cells relevant to asthma and COPD are controlled by type I PI3Ks, especially
PI3Kδ and γ. Thus, selective PI3Kγ and/or PI3Kδ inhibitors might have relevant anti-
inflammatory activity in COPD.
3.2. Cytokine and chemokine antagonists
In patients with COPD, protein and/or mRNA levels of different pro-inflammatory cytokines
and chemokines have been found to be increased compared with subjects without COPD.
Among these, TNFα or TNFR levels, soluble IL-1 receptor antagonist (sIL-1Ra), CCL2
(monocyte chemoattractant protein 1, MCP-1) and its receptor CCR2, CCL3 (macrophage
inflammatory protein 1α, MIP-1α) and CCL4 (MIP-1β) and their receptor CCR5, CXCL8
(IL-8), and CXCL10 (interferon-inducible protein 10, IP-10) can be discerned as pro-
inflammatory factors. In addition to the inflammatory effects, recent studies provided more
evidence that cytokines and chemokines are also involved in tissue remodelling apart from
growth factors, pointing to cytokine-driven effects of inflammatory cells on epithelial wound
repair [74].
Several recent reviews point to the development of novel antagonists of cytokines, chemokines
or their receptors [74–76]. These molecules may reduce gene expression, impair production
or secretion of mature proteins, antagonize binding of cytokines and chemokines to their
receptors or inhibit receptor signal transduction. Antibodies and solubilized receptors like
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TNFR often scavenge solubilized cytokines and chemokines, or prevent binding of these
proteins to their receptors. Small molecules 1) prevent binding of cytokines and chemokines
to their receptors by non-activating mimicry of cytokines or chemokines, or 2) prevent
intracellular signal transduction activation, or 3) interfere with gene expression and translation
by direct inhibition of transcription factors (like IKK2 inhibition) or mRNA binding via small
interference (si) RNA or antisense mRNA.
3.2.1. TNFα and receptors antagonists—Concentration of TNFα and soluble TNFα
receptor are increased in the sputum of COPD patients [77,78]. Experimental animal models
show that TNFα over-expression induces the pathological changes similar to emphysema and
pulmonary fibrosis. COPD patients with cachexia have also increased release of TNFα and
soluble TNFα receptor in circulation, which may be a factor contributing to the weight loss in
patients with the disease [79]. Therefore, several drugs have been developed to reduce TNFα
levels, of which some have been approved by e.g. the Federal Drug Administration for
treatment of RA, ankylosing spondylitis, Crohn’s disease, or psoriasis. These approved drugs
include etanercept (soluble human TNFR2), infliximab (chimeric human/mouse IgG1 antibody
against TNFα), and adalumimab (human IgG1 antibody against TNFα). Many others are being
developed in order to enhance efficacy, reduce side effects due to frequent subcutaneous
injection, increase bioavailability or protection to proteolytic degradation by coupling to
polyethylene glycol chains, or reduce immunogenicity by humanization of antibodies or
designing small molecules. In contrast to treatment of refractory asthma, recent clinical phase
II trials demonstrated that in general COPD patients do not benefit from treatment with
infliximab in terms of quality of life, lung function or physical endurance [80,81]. Patients with
moderate to severe asthma may benefit from treatment with either infliximab or etanercept.
However, as pointed out in several reviews [76,82] infliximab is just one of the many
antagonists of TNFα and its receptors and its effect may need longer treatment instead 6 weeks
of treatment. Three infusions of infliximab over 6 weeks reduced the number of exacerbations
as well as sputum levels of TNFα, IL-6, CXCL8 and CXCL10 but not peak expiratory flow or
inflammatory cell count in sputum of patients with moderate asthma [83]. Other studies
demonstrated that twice-weekly treatment with etanercept during 10 to 12 weeks improved the
bronchial hyperresponsiveness (BHR, expressed as PC20), post-bronchodilator FEV1 and the
quality of life of patients with refractory, severe asthmatic patients [84,85]. Treatment of
asthmatics with marimastat, an inhibitor of TNFα and MMP activation, also reduced BHR but
failed to significantly reduce sputum inflammatory cell numbers, asthma symptoms, FEV1 or
bronchodilator use [86]. Future studies should sort out whether long-term treatment or
treatment with different TNFα antagonists are beneficial to all COPD patients or only a specific
phenotype/population of COPD patients [80,82].
3.2.2. CXCL1, CXCL8 and receptors antagonists—CXCL1 (GROα) and CXCL8
(IL-8) are produced by both structural and inflammatory cells including macrophages, and are
chemotactic and activate inflammatory cells while IL-8 also induces neutrophils to degranulate
and causes an oxidative burst. Both bind to their receptor CXCR2 whereas IL-8 binds also to
CXCR1. Both receptors are expressed on neutrophils while CXCR2 is also expressed on other
inflammatory cells including a subset of CD8+ T cells, mast cells and macrophages.
Concentration of IL-8 is very high in the sputum of patients with COPD and is correlated with
the disease severity [77,87]. Blocking antibodies to IL-8 and related chemokines inhibit certain
types of neutrophilic inflammation in animals [88] and reduce the chemotactic response of
neutrophils to sputum from COPD patients [89,90]. Several CXCR2 and IL-8 antagonists are
available, some of which were in clinical trial for COPD [76]. Updated information shows that
either the testing of these drugs is discontinued (like the antibody ABX-IL-8 against human
IL-8) or is not to be found in the public domain. Hence, little is known yet on treatment of
patients with COPD with IL-8 or CXCR2 antagonists. The small molecule CXCR2 antagonist
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SB-656933 (by GSK) has recently been demonstrated to inhibit the IL-8-induced expression
of CD11b molecules on peripheral blood neutrophils from COPD patients [91]. The antagonist
was mentioned to enter clinical trial studies for COPD in 2005, but is not so in GSK’s pipeline
of 2006/2007. Data from these studies have not yet been published. SB-265610 is a small
molecule inhibiting CXCR2. Studies demonstrated that hyperoxia in newborn rats led to
pulmonary inflammation by neutrophils and the formation of ROS and RNS mediating
impaired lung development and lipid peroxidation [92,93]. Treatment with SB-265610 reduced
airway neutrophilia, radical formation, lipid peroxidation and protein nitration, as well as
improved conservation of lung development and lung function. This reflects to the importance
of reducing neutrophilia in order to reduce reactive species formation, lipid peroxidation or
nitration, and tissue destruction or alterations. Data from other studies supported the
effectiveness of IL-8 or CXCR2 antagonists in reducing neutrophilia in vivo in rodents and
inhibition of neutrophil activation and degranulation in vitro [76,94]. These data point to the
potential need for development of novel antagonists of CXCR1, CXCR2 or their ligands
CXCL1 and IL-8. Recent studies showed that novel thiazolopyrimidine, cyclobutenedione (e.g.
SCH 527123), or imidazolylpyrimidine CXCR2 antagonists had a good oral bioavailability in
rats with reasonable pharmacokinetics (half life of at least 1.2h) [95–97], and inhibition of
CXCL1- or IL-8-induced chemotaxis of cells [95,96].
3.2.3. CCL2 (MCP-1) and CCR2 antagonists—Patients with chronic bronchitis have
higher CCL2 in the BALF than healthy non-smokers [98]. In bronchial biopsy specimens,
CCL2 mRNA bronchiolar epithelium expression, including the expression of its receptor
(CCR2 in macrophages), was also increased in COPD patients when compared to subjects
without COPD [99]. In addition, the level of CCL2 in sputum samples of smoking COPD
patients were also increased when compared to non-smokers and healthy smokers [100].
Furthermore, CCL2 levels in the exhaled breath condensate from COPD patients correlated
with the degree of airflow obstruction as measured by FEV1/FVC ratio [101]. These data
support a major role for CCL2 and CCR2 in airway remodeling and inflammation directly or
via macrophages. Antagonists of CCR2 or CCL2 may, therefore, be an attractive approach to
therapeutic treatment of COPD.
The humanized monoclonal antibody MLN1202 (by Millennium) against CCR2 is currently
in phase II for treatment of chronic inflammatory diseases like multiple sclerosis and
artherosclerosis. Clinical data from these studies have not yet been published. Other inhibitors
in clinical trial include the small molecule CCR2 inhibitors CCX915 (by ChemoCentryx) for
multiple sclerosis (phase I), INCB3284 (by Incyte/Pfizer) which is in phase IIa for treatment
of RA, and the monoclonal antibody ABN912 against CCL2 (by Novartis) for COPD (phase
I) and RA (phase II). Recently, patients with RA did not clinically and immunohistologically
respond to a 2-week treatment with ABN912 [102]. Serum levels of CCL2 increased clearly
after treatment (doses higher than 1 mg/kg body weight), and chemotactic complexes of the
antibody with CCL2 were formed. This may hamper the treatment of patients with COPD;
however these results have to be awaited. Several other compounds based on butyramides or
γ-aminoamides were recently developed as specific CCR2 antagonists with a good oral
bioavailablity in rats [103,104]. Others are in preclinical phase, including INCB8696,
JNJ-27553292, SKL-2841 and INCB3344. INCB3344 is a rodent CCR2 small molecule
antagonist [105]. The compound was shown to inhibit macrophage influx in a mouse model
for delayed hypersensitivity.
3.3. Anti-proteinases
3.3.1. Neutrophil elastase inhibitor—Neutrophil elastase is a serine protease that is
synthesized in the neutrophils and secreted following neutrophils activation. One of the major
actions of neutrophil elastase is its ability to degrade matrix proteins. Neutrophil elastase
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increases MMPs activity by directly activating MMPs such as MMP-9 [106] and by
inactivating the endogenous MMP inhibitor, tissue inhibitor of matrix metalloproteinase
(TIMP) [107], thus potentially enhancing the role of MMPs in COPD. It also has a pro-
inflammatory role in COPD pathogenesis [108,109]. In the absence of neutrophil elastase,
neutrophils had difficulty escaping the capillary to the lung interstitium and alveolar space
[109]. This was not due to an inability of neutrophils to penetrate basement membranes in the
absence of NE [110]. NE is required to dissociate the CD11/CD18-ICAM-1 complex tethering
the neutrophil to the endothelium [111]. Similarly, marked suppression of macrophage
accumulation in the lungs in neutrophil elastase-deficient mice exposed to cigarette smoke
[109]. Moreover, neutrophil elastase has also been reported to stimulate mucin secretion and
modulate apoptosis of human lung epithelial cells. Therefore, neutrophil elastase may play a
role in emphysema and lung remodeling through matrix degradation and by inducing apoptosis.
In cigarette smoke models the neutrophil elastase knockout mice is protected from emphysema
development and this effect is accompanied by an inhibition of both neutrophils and
macrophages recruitment [109]. Treatment with α-1-anti-trypsin inhibited emphysema
development and reduced pulmonary neutrophils and macrophages recruitment [112,113]. The
role of α-1-antitrypsin replacement therapy in slowing the progression of α1-antitrypsin-
deficiency related emphysema seems likely, but has not yet been proven by appropriate
randomized placebo trials. Similarly, a small molecule neutrophil elastase inhibitor, ZD0892,
reduced cigarette smoke induced emphysema and pulmonary cells recruitment in a guinea pig
model [114]. These studies suggest inhibition of neutrophil elastase can be anti-inflammatory
in addition to preventing emphysema development.
The search for potent, safe oral inhibitors of neutrophil elastase has been going on for over 20
years and many of the compounds that progressed into clinical development failed because of
poor PK and low therapeutic index. Subsequently, tripeptidyl trifluoromethyl ketones were
developed that had a better oral profile, although these molecules were not fully optimized for
oral delivery [115] and monocyclic beta lactam neutrophil elastase inhibitor were also
identified [116]. More recently, both GSK (GSK-311366) and ONO Pharmaceuticals
(ONO6818) have had oral compounds in Phase I/II. However, they failed in early clinical trials
and thus far no oral elastase inhibitors have been evaluated fully in Phase II COPD trials. The
AstraZeneca protease inhibitor AZD3342 (thought to be an elastase inhibitor) is assessed in
Phase II studies and Bayer has an inhibitor in Phase I.
Protein inhibitors of neutrophil elastase administered via nebulisation are also being pursued
and supportive data has been obtained for inhaled recombinant α1-antitypsin in mouse cigarette
smoke models. The probability of inhaled combination products consisting of elastase
inhibitors with bronchodilators is low. However, the opportunity for safe long acting inhaled
elastase inhibitors with low systemic bioavailability that are suitable for combination with
bronchodilators is being pursued by Argenta Discovery.
3.3.2. MMPs inhibitor—MMPs have been suggested from recent studies as the major
proteolytic enzymes involved in the pathogenesis of COPD. Increased levels of MMP-1 and
MMP-9 have been detected in bronchoalveolar lavage fluid of patients with emphysema
[117]. As compared with healthy subjects, patients with COPD have a marked increase in
expression and activity of MMP-2, MMP-9 and MT1-MMP in their lung parenchyma [118]
and increased gelatinolytic activity linked to MMP-2 and MMP-9 in their sputum [119,120].
In BALF of smokers with emphysema, an increase of collagenolytic activity, probably due to
elevated levels of MMP-8, is measured when compared to smokers without emphysema
indicating that injury to the collagen network of the lung is also a part of the disease. When
studied ex vivo, alveolar macrophages from patients with emphysema express more MMP-1
and MMP-9 than macrophages from healthy subjects suggesting that macrophages are the main
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cellular source of MMP-1 and MMP-9 in COPD [121]. As it has a potent elastolytic activity,
MMP-12 is thought to play a determinant role in development of COPD and emphysema.
Experimental data show that mice exposed to cigarette smoke express more MMP-12 mRNA
than non-exposed mice [122]. MMP-12 is also markedly increased in induced sputum from
patients with stable COPD compared with controls [123]. MMP-12 gene deletion in mice
protects from the development of emphysema after long term exposure to cigarette smoke
[124]. Alveolar macrophages were considered to be the unique source of MMP-12
(macrophage metalloelastase). Taken together, these elements suggest that MMP-12 could be
seriously considered as a potential target for COPD treatment [125]. Indeed, some reports
establish the potential interest for a MMP inhibition-based approach in COPD, based on results
obtained in animal models. Orally bioavailable synthetic MMP inhibitors were showed to
decrease the rapidity of alveolar destruction in murine and Guinea Pig models of tobacco smoke
exposure. Although non-specific MMP inhibitors, such as marimastat, seem to have substantial
musculoskeletal side-effect [126], these adverse effects could be reduced by increasing the
selectivity for specific MMP or by targeting delivery to lung parenchyma. Interestingly, many
MMP inhibitors may actually improve the progression of emphysema but perhaps are not so
potent in preventing airway inflammation. Many potential drugs such as BMS-561392 and
GW3333, which can inhibit MMPs and TNF-α converting enzyme, are still in preclinical
development or in clinical trial phases for diseases other than COPD. In addition, some
antibiotics such as minocycline and roxithromycin have MMPs inhibitory effect and improve
the MMPs/TIMP imbalance as well. Therefore, these drugs may be other candidates to improve
the progression of COPD.
3.4 HDACs modifiers
NF-κB being a pro-inflammatory transcription factor, on activation binds to specific
recognition sequence motifs in DNA and subsequently interacts with a multitude of co-
activator molecules, such as cAMP-response-element-binding protein (CREB), CREB-
binding protein (CBP), p300 and p300/CBP-associated factor (pCAF). These co-activators act
as molecular switches of transcription and acetylate histones by their intrinsic histone
acetyltransferase (HAT) activity [127,128]. Acetylation of core histones allow DNA
unwinding and thus access to wide variety of transcription factors [127]. The transcriptional
process can be reversibly switched off by deacetylation of acetylated histones, thus rewinding
the exposed DNA, consequently leading to gene silencing. The deacetylation of acetylated
histones is brought about by HDACs, which act as co-repressors, in association with other co-
repressor proteins that are concomitantly recruited. Ito and co-workers have shown a role for
histone acetylation and deacetylation in IL-1β-induced TNFαrelease in alveolar macrophages
derived from cigarette smokers [129]. The activity and expression of HDAC, a transcriptional
corepressor, was decreased in COPD due to oxidative stress and consequently cytokine
transcription was increased [71]. Furthermore, both cigarette smoke/H2O2 and TNFα caused
an increase in histone acetylation (HAT activity) leading to IL-8 expression in monocytes and
alveolar epithelial cells both in vitro and in vivo in rat lungs [130–132]. Since all inflammatory
processes involve acetylation and deacetylation of histones (chromatin remodeling) [133],
HDACs therefore are attractive targets for anti-inflammatory therapies.
Glucocorticoid suppression of inflammatory genes requires recruitment of HDAC2 to the
transcription activation complex by the glucocorticoid receptor [129,134]. This results in
deacetylation of histones and a decrease in inflammatory gene transcription. A reduced level
of HDAC2 was associated with increased proinflammatory response and reduced
responsiveness to glucocorticoids in alveolar macrophages obtained from smokers [129–132,
134]. Culpitt and co-workers have shown that cigarette smoke solution stimulated release of
IL-8 and GM-CSF, which was not inhibited by dexamethasone, in alveolar macrophages
obtained from patients with COPD compared to that of smokers [135]. They suggested that
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the lack of efficacy of corticosteroids in COPD might be due to steroid insensitivity of
macrophages in the respiratory tract. Recent study showed that overexpression of HDAC2 in
glucocorticoid-insensitive alveolar macrophages from patients with COPD is able to restore
glucocorticoid sensitivity [72]. Mechanisms study demonstrated that HDAC2 acts by
deacetylating glucocorticoid receptor, thereby enabling p65-NF-κB association and
subsequent attenuation of proinflammatory gene transcription. Thus, the cigarette smoke/
oxidant-mediated reduction in HDAC2 levels and activity in alveolar epithelial cells and
macrophages will not only increase inflammatory gene expression but will also cause a
decrease in glucocorticoid function in patients with COPD.
Consequently, a potential means by which to treat COPD would be to increase HDAC2
expression and activity such that steroids regain their anti-inflammatory activity. Co-
incubation of cells with NAC and H2O2 protects HDAC2 from down regulation and reduction
of specific activity [131]. In addition, it has been reported that theophylline and PI3K inhibitor
(LY294002) have a similar effect in lung macrophage cells, increasing HDAC2 expression
and re-sensitizing the cells to steroids [73,136]. Alternative means of upregulating HDAC2
activity would be of great interest for potential combination therapies for steroid-insensitive
COPD.
4. Conclusion
After smoking cessation inflammation still goes on which may hamper tissue repair. Hence,
an effective treatment of patients with COPD not only needs stopping exposure to toxic
compounds like smoke, but also needs attenuation of excessive inflammation. Several anti-
inflammatory mechanisms are being investigated in COPD patients and the data generated
within next 5 years will indicate if significant anti-inflammatory activity can be achieved in
COPD patients and whether this results in improved clinical outcomes. Oral drugs have the
advantage of improved compliance over inhaled agents and may reduce the chronic systemic
inflammation present in COPD patients in addition to reducing the inflammation within the
lungs. Inhaled therapies may have the advantage of targeting pulmonary inflammation while
have low systemic exposure and improved therapeutic index. In addition, development of
specific isoform inhibitors of inflammatory signaling pathway is also way to reduce the adverse
effect of broad spectrum inhibitor. Another approach is to enhance negative homeostatic
signals such as anti-inflammatory IL-10 would counteract the ongoing airway inflammation
in COPD based on the finding showing that IL-10 level in sputum is reduced in COPD and
smoker [137]. Furthermore, combination of drugs can be explored with the aim of enhancing
the efficacy of mono-therapy and reducing the side action, e.g. HDAC2 modifiers restore the
steroids sensitivity to COPD.
ABBREVIATIONS
BALF, Bronchoalveolar lavage fluid
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MMPs, Matrix metalloproteinases
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PDE4, Phosphodiesterase 4
PI3K, Phosphoinositide-3-kinase
TIMP, Tissue inhibitor of matrix metalloproteinase
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Figure 1. Pulmonary inflammation in COPD and emerging anti-inflammatory therapy
Exposure to cigarette smoke in susceptible individuals leads to an abnormal inflammation
which appears to be self-perpetuating and is perhaps linked to infection. Alveolar macrophages
and pulmonary epithelial cells release all kinds of inflammatory mediators in response to
cigarette smoke which activate and stimulate migration of pulmonary inflammatory cells
including neutrophils, macrophages and lymphocytes. The chronic and persistent inflammation
that ensues is thought to be responsible for both the symptoms of disease and also the
progressive decline in lung function that is seen in COPD patients. The loss of airway function
appears to be related to the destruction of alveoli resulting in a loss of elasticity linked to
increased protease activity, and obstruction and fibrosis of the small airway as a result of
inflammation and mucus hyper-secretion. Emerging anti-inflammatory therapies under clinical
investigation attack this chronic pulmonary inflammation via several strategies. Signaling
pathway inhibitors such as PDE4 inhibitors, p38 MAPK inhibitors, NF-κB signaling inhibitors
and PI3K inhibitors are in development. Reduction of pleiotropic inflammatory cytokines such
as TNF-α using monoclonal antibodies that target the ligands, or soluble receptors that bind
and inactivate TNF-α may also reduce the inflammatory burden in the lung. Targeting
chemokines such as MCP-1 and IL-8 may reduce the influx of inflammatory cells into the lungs
from the circulation by reducing the chemotactic gradient. Inhibition of protease activity in the
lung may attenuate lung tissue damage and reduce the numbers of lung neutrophils. Increase
HDAC2 expression restores the steroids sensitivity for treatment of COPD. Reducing the
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severity of inflammation in the lung may improve lung function and slow the progression of
COPD.
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Figure 2. Activation of p38 MAPK, NF-κB and PI3K pathway in COPD and possible therapeutic
targets
Cigarette smoke-mediated oxidative stress can result in activation of various kinases [p38
mitogen-activated protein kinase (p38 MAPK), IκB kinase (IKK) and phosphoinositide 3-
kinase (PI3K)] leading to release of pro-inflammatory mediators by activating transcription
factor NF-κB. A reversible PI3K inhibitor, LY294002, can restore defective HDAC2
expression and activity (possibly restores steroid efficacy) which were shown in the lungs of
patients with COPD. Therefore, these kinases would be possibly therapeutic targets although
these inhibitors/modifiers of above-mentioned kinases have not yet been proven by appropriate
randomized placebo trials.
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